UBS Maintains Buy on Boston Scientific, Lowers Price Target to $67

Benzinga Newsdesk www.benzinga.com Negative 69.9%

Neg 69.9% Neu 0% Pos 0%

UBS analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $74 to $67.

Comments

No comments yet. Be the first!